Bert O'neil
Expertise in
10
conditions

Dr. Bert O'neil

Oncology
Office
7979 N Shadeland Ave Ste 200, 
Indianapolis, IN 
Offers Telehealth
Expertise in
10
conditions
Office
7979 N Shadeland Ave Ste 200, 
Indianapolis, IN 

Overview

Bert O'neil is an Oncologist in Indianapolis, Indiana. Dr. O'neil is highly rated in 10 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, Familial Pancreatic Cancer, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 122 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in IN

Hospital Affiliations

Community Hospital North
Community Hospital East

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Office
7979 N Shadeland Ave Ste 200, Indianapolis, IN 46250
Other Locations
Univ. Radiation Oncology Associates Inc.
535 Barnhill Dr, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Other, Drug
Study Drugs: Adavosertib, Gemcitabine hydrochloride
Study Phase: Phase 2
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab
Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drugs: 5-Fluorouracil, Leucovorin, Irinotecan, Bevacizumab
Study Phase: Phase 2
Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198
Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198
Enrollment Status: Completed
Publish Date: January 01, 2025
Intervention Type: Other, Drug
Study Drugs: mFOLFIRINOX, Ramucirumab
Study Phase: Phase 2
A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib in Patients With Advanced KRAS Mutant Cancer
A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib in Patients With Advanced KRAS Mutant Cancer
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Futibatinib, Binimetinib
Study Phase: Phase 1
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Enrollment Status: Completed
Publish Date: March 22, 2023
Intervention Type: Drug
Study Phase: Phase 2
Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients
Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients
Enrollment Status: Completed
Publish Date: October 18, 2022
Intervention Type: Drug
Study Phase: Phase 1
Molecularly Driven, Immune-Based, Maintenance Niraparib and Dostarlimab in Advanced Stage Cholangiocarcinoma
Molecularly Driven, Immune-Based, Maintenance Niraparib and Dostarlimab in Advanced Stage Cholangiocarcinoma
Enrollment Status: Withdrawn
Publish Date: June 29, 2022
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Trial of Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
A Phase II Trial of Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Terminated
Publish Date: August 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
Enrollment Status: Terminated
Publish Date: June 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 16 Less Clinical Trials

122 Total Publications

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 05, 2025
Similar Doctors
Expertise in
20
conditions
Dr. Lawrence Einhorn
Oncology
Expertise in
20
conditions
Dr. Lawrence Einhorn
Oncology

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (11.1 miles away)
317-274-3515
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lawrence Einhorn is an Oncologist in Indianapolis, Indiana. Dr. Einhorn is highly rated in 20 conditions, according to our data. His top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Orchiectomy, and Bone Marrow Transplant.

Nasser Hanna
Expertise in
21
conditions
Dr. Nasser Hanna
Oncology
Expertise in
21
conditions
Dr. Nasser Hanna
Oncology

Office

535 Barnhill Dr Ste 473, 
Indianapolis, IN 
 (10.2 miles away)
317-944-5000
Languages Spoken:
English
See accepted insurances

Nasser Hanna is an Oncologist in Indianapolis, Indiana. Dr. Hanna is highly rated in 21 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Testicular Cancer, Orchiectomy, and Bone Marrow Transplant.

Expertise in
18
conditions
Dr. Patrick Loehrer
Oncology
Expertise in
18
conditions
Dr. Patrick Loehrer
Oncology

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (11.1 miles away)
317-278-7418
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Patrick Loehrer is an Oncologist in Indianapolis, Indiana. Dr. Loehrer is highly rated in 18 conditions, according to our data. His top areas of expertise are Thymic Epithelial Tumor, Colorectal Cancer, Pancreatic Cancer, Pancreaticoduodenectomy, and Thymectomy.

Frequently Asked Questions about Dr. Bert O'neil

How do I make an appointment with Dr. Bert O'neil?

You can book an appointment with Dr. Bert O'neil by calling their office at 317-621-4300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bert O'neil a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bert O'neil is classified as an Elite expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bert O'neil specialize in?

While Dr. Bert O'neil is a Oncology, they have specific expertise in Pancreatic Cancer, Colorectal Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Bert O'neil participate in research or clinical trials?

Yes. Dr. Bert O'neil has published 122 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Bert O'neil's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bert O'neil accept my insurance?

Dr. Bert O'neil accepts most major insurance plans, including Anthem BCBS and CareSource. We recommend calling the office directly at 317-621-4300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. O'neil's expertise for a condition
ConditionClose
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile